The device company’s Senza High-Frequency Spinal Cord Stimulation System delivers electrical pulses at a higher rate than devices currently used for spinal cord stimulation, according to the release. Data from previous European clinical studies suggest that this high-frequency waveform may be effective in treating lower back pain and other types of chronic pain that often do not respond to conventional spinal cord stimulation.
The FDA-approved study will consist of a randomized, controlled trial that will enroll approximately 300 patients across up to 15 U.S. centers. Patients will be randomized to receive either Nevro’s high-frequency or conventional low-frequency spinal cord stimulation.
Related Articles on Pain Management:
Laser Spine Institute Launches Employee Wellness Program
NIH Names 11 Centers of Excellence in Pain Education
15 New Statistics on Pain Management Case Volume in ASCs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
